Brief: Hcw Biologics Inc Says Masonic Cancer Center Announced First Patient Was Dosed In Phase 1 Clinical Trial To Evaluate HCW9218
19/05/2022 22:40
May 19 (Reuters) - HCW Biologics Inc HCWB.O :
* HCW BIOLOGICS INC - ON MAY 19, MASONIC CANCER CENTER
ANNOUNCED
FIRST PATIENT WAS DOSED IN PHASE 1 CLINICAL TRIAL TO EVALUATE
HCW9218
Further company coverage: HCWB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hcw Biologics
See all newsBrief: Hcw Biologics Maintains Momentum Toward Completion Of Ind Application For Clinical Study To Evaluate Lead T-Cell Engager In Solid Tumors
Brief: HCW Biologics Registers Resale Of Up To 1.81 Mln Shares Of Common Stock By Selling Stockholder- SEC Filing
NASDAQ RESUMED AT 10:34 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:29 AM
NASDAQ RESUMED AT 10:29 AM